Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1074426 | 0.89 | PDE4B (0.37) | GRM1PDE4BPDE4DPTGS2PTGS1 | |
| SCHEMBL1073760 | 0.89 | POLB (0.36) | CYP2C9PTGS2PTGS1HPGD | |
| SCHEMBL1224856 | 0.88 | GRM5 (0.36) | CYP2C9PTGS2PTGS1 | |
| SCHEMBL1075218 | 0.88 | HSP90AA1 (0.35) | CYP2C9PTGS2PTGS1BRD9ALDH1A1 | |
| SCHEMBL1074053 | 0.83 | GRM1 (0.40) | GRM1PDE4BPDE4DPTGS2PTGS1 | |
| SCHEMBL1074755 | 0.81 | SMN1; SMN2 (0.37) | PDE4BP2RX7CYP1A2 | |
| SCHEMBL1074256 | 0.80 | GRM1 (0.43) | GRM1PDE4BPDE4DBRD9 | |
| SCHEMBL19953168 | 0.78 | SMN1; SMN2 (0.36) | PTGS2PTGS1 | |
| SCHEMBL1074241 | 0.77 | SMN1; SMN2 (0.36) | PTGS2PTGS1BRD9ALDH1A1CYP1A2 | |
| SCHEMBL1075665 | 0.77 | PTGS2 (0.34) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110045101-A1 | FUNGICIDAL SUBSTITUTED AZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-02-24 | — | — | US | claimed |
| EP-2274284-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. Du Pont de Nemours and Company (US) | 2011-01-19 | — | — | EP | claimed |
| WO-2009137538-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-12 | — | — | WO | claimed |
| WO-2009137651-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-12 | — | — | WO | claimed |
| WO-2011056463-A2 | FUNGICIDAL MIXTURES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110045101-A1 | FUNGICIDAL SUBSTITUTED AZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2274284-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. Du Pont de Nemours and Company (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009137538-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137651-A2 | FUNGICIDAL SUBSTITUTED AZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045101-A1 | FUNGICIDAL SUBSTITUTED AZOLES | CBR3, NOX3, CBR1 | GRM1 1277/4885CYP2C9 33/4885PDE4B 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.